NSC-42834

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：NSC-42834	Purity：98% min
CAS NO：195371-52-9	Solubility：DMSO : ≥ 43 mg/mL (124.84 mM)
Molecular Formula：C₂₃H₂₄N₂O	Package：Package according to customer requirements
Molecular Weight：344.449	Storage：Store at -20℃

Quality control

Remarks

NSC 42834 a novel specific inhibitor of Jak2, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.

JAK Inhibitors Related Products:

Ruxolitinib; Ruxolitinib phosphate; Tofacitinib; AZD1480; Momelotinib; Gandotinib; AZ960; Pacritinib; XL019; Upadacitinib; Decernotinib; Filgotinib; GLPG0634 analogue; FLLL32; AG-490 (Tyrphostin B42); Itacitinib; Go6976; Baricitinib; Oclacitinib; Oclacitinib maleate ; WP1066

References

[1]. Jacqueline Sayyah, Andrew Magis, David A. Ostrov, et al. Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth . Mol Cancer Ther 2008;7(8):2308-18.

[2]. Jacqueline Sayyah, Peter P. Sayeski. Jak2 inhibitors: Rationale and role as therapeutic agents in hematologic malignancies. Current Oncology Reports. 2009, 11(2): 117-124.

[3]. Ehab Atallah , Srdan Verstovsek . Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Review of Anticancer Therapy. 2009,9 (5):663-670.